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Abstract
Background: A "physiologically based pharmacokinetic" (PBPK) approach uses a realistic model
of the animal to describe the pharmacokinetics. Previous PBPKs have been designed for specific
solutes, required specification of a large number of parameters and have not been designed for
general use.
Methods: This new PBPK program (PKQuest) includes a "Standardhuman" and "Standardrat" data
set so that the user input is minimized. It has a simple user interface, graphical output and many
new features: 1) An option that uses the measured plasma concentrations to solve for the time
course of the gastrointestinal, intramuscular, intraperotineal or skin absorption and systemic
availability of a drug – for a general non-linear system. 2) Capillary permeability limitation defined
in terms of the permeability-surface area products. 4) Saturable plasma and tissue protein binding.
5) A lung model that includes perfusion-ventilation mismatch. 6) A general optimization routine
using either a global (simulated annealing) or local (Powell) minimization applicable to all model
parameters.
Results: PKQuest was applied to measurements of human propranolol pharmacokinetics and
intestinal absorption. A meal has two effects: 1) increases portal blood flow by 50%; and 2)
decreases liver metabolism by 20%. There is a significant delay in the oval propranolol absorption
in fasting subjects that is absent in fed subjects. The oral absorption of the long acting form of
propranolol continues for a period of more than 24 hours.
Conclusions:  PKQuest provides a new general purpose, easy to use, freely distributed
[www.pkquest.com] and physiologically rigorous PBPK software routine.
Background
The expression "physiologically based pharmacokinetic
model" (PBPK) describes an approach where the drug ki-
netics are modeled using a realistic physiological descrip-
tion of the animal. This has now become a standard
approach to pharmacokinetics and has been applied to
many different compounds [1]. Despite this, most human
drug studies still rely on approximate compartmental
pharmacokinetic techniques and do not attempt a com-
plete physiological model. One reason for this is that de-
tailed kinetic information for the different organs is not
available in humans to the same extent as it is in animal
studies. A second reason is that PBPK models are still
somewhat difficult to use and remain a tool primarily of
specialists.
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This paper, along with the accompanying papers [2–4],
describes a new PBPK modeling program (PKQuest) that
is designed to overcome both of these problems. The first
problem (lack of information) is avoided by preprogram-
ming a large set of data about kinetics in different organs
that can be called as default variables applicable to what-
ever solute is being investigated. The second problem
(ease of use) is overcome by using a simple interface and
a graphical and printed output that provides a complete
description of the pharmacokinetics. Despite this ease of
use, PKQuest provides a rigorously accurate PBPK applica-
ble to all the different physiological and biochemical
properties of the different compounds that are commonly
investigated.
This first paper introduces the general features of the pro-
gram, describes the mathematical details and explains the
simple interface that has been designed to use it. PKQuest
has incorporated a large number of features, some of
which have been developed and introduced for the first
time (see below). Some of these features are illustrated in
this paper by using PKQuest to obtain new information
about the human pharmacokinetics of propranolol. This
is an intensively investigated area. For example, a search in
PubMed for the terms "propranolol" AND "pharmacoki-
netics" yielded 1306 references. Despite this, there are still
several important questions remaining about its behavior
in man. In particular, the rather peculiar effect of food in-
take on plasma levels remains unexplained [5]: Meals de-
crease the plasma levels when propranolol is given
intravenously (IV), and increase the plasma levels when
propranolol is given orally (PO). Since it has been shown
that gastrointestinal absorption is complete [6], this meal
effect must result from a food induced change in the me-
tabolism, distribution or rate of absorption. Since liver
propranolol metabolism is partially limited by liver blood
flow [7], the meal induced decrease in the plasma level of
the IV administered propranolol can be explained by the
increase in liver blood flow that has been shown to be as-
sociated with a meal [5,8–10]. However, this would not
explain the meal induced increase in plasma levels follow-
ing the oral propranolol. PKQuest will be used to try and
provide an explanation of this behavior. This analysis is
based primarily on the experimental data of Olanoff et. al.
[5] in which the plasma propranolol levels were measured
after simultaneous IV and PO administration, eliminating
the effects of individual variation from these measure-
ments. Requiring a single set of parameters to fit both the
simultaneous IV and PO plasma concentration data im-
poses a strong limitation on the model. Comparing the
PBPK parameter set for the fed and fasted case then pro-
vides quantitative information about the effect of meals
on propranolol pharmacokinetics. This analysis makes ex-
tensive use of the novel PKQuest feature that uses the
blood levels following an oral dose to calculate the time
course of the intestinal PO absorption.
In the last section, PKQuest will be used to quantitate the
time course of intestinal absorption of a sustained release
form of propranolol.
The modeling program, along with the detailed applica-
tions described in these papers, is freely available on the
Web at  [www.pkquest.com].
Methods
Flow diagram
PKQuest uses the conventional PBPK flow diagram [1]
shown in fig. 1. Each box corresponds to a well-mixed
compartment and each arrow is an input or output to the
compartment determined by the blood flow. The different
compartments are numbered from 0 (vein) to 11 (lipid).
Each compartment is described by the total organ blood
flow (liters/min) and the total weight (Kg). In PKQuest
the names shown in fig. 1 can be used in place of the num-
bers. For example the muscle blood flow can be described
either by F[7] or F [muscle]. Table 1I lists the values of or-
gan weight and the blood flow per organ weight for each
organ for the standard human (70 Kg). These organ
weights are for the default value of 20% body fat. They are
scaled depending on the value of "Fat" that is input. The
"portal" compartment corresponds to all the organs
drained by the portal vein (stomach, small and large intes-
tine, pancreas and spleen) with a blood flow equal to that
in the portal vein. The "liver" blood flow corresponds to
the hepatic artery. The compartment labeled "other"
groups all the other organs with a flow and weight adjust-
ed to account for the total body weight (70 Kg) and the to-
tal default cardiac output (6.06 liters/min). For a
complete listing of all parameters and constants used in
PKQuest, download the file gensolve.mws from the
PKQuest web site  [www.pkquest.com] and view the rou-
tines "standardman()" and "defaultpar()".
A number of other properties are associated with each
compartment such as the water volume fraction of the tis-
sue (wfract, liters/Kg), the fraction of the compartment
water that is extracelluar (ecf), the capillary clearance
(flcear), etc. The critical variable describing the kinetics is
the free water concentration c[i] for each compartment i.
This is the concentration that determines the rate of ex-
change across the capillary. It is related to the experimen-
tal concentration C[i] (amount/Kg) by the parameter fw[i]
which is the fraction of the total solute in compartment i
that is free in the water phase (c = fw*C/wfract). The pa-
rameter fw is determined by factors such as protein bind-
ing and lipid solubility. Although fw is the parameter used
in the actual calculations, its value is usually input in
terms of other parameters, such as the lipid/water parti-BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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tion coefficient [2] or the protein binding [4]. For the pro-
pranolol calculations, fw[i] is related to the input
parameters ktiss[i] (the ratio of tissue to plasma concen-
tration) and freepl (the fraction free in plasma) by the re-
lation: fw[i] = freepl*watfr[i]/(watfrpl*ktiss[i]) where
watfr[i] and watfrpl are the water fractions in tissue i and
in the plasma.
Each compartment can have a metabolic component (Q)
described either by the Michaelis-Menten parameters Vm
and Km (Q[i] = Vm[i]*c[i]/(Km[i]+c[i])) if the metabo-
lism saturates or by a metabolic clearance (Tclr) if the me-
tabolism is linear. The kidney is a special case, removing
solute either via filtered renal clearance (rclr) or by tubule
secretion (described by Vm[kidney], Km[kidney] and
Tclr[kidney]). (The default is no tubule secretion or clear-
ance). Each compartment can also have its own unique in-
put from outside the body (cinput[i]). The standard
inputs are to the vein, lung or GI tract. It is assumed that
the PO absorption goes directly into the liver via the por-
tal vein. This choice was made (as opposed to PO input
into the portal compartment) because the solute absorbed
by, e.g., the small intestine is picked up by the villous cap-
illaries and removed in the portal vein before it distributes
in the entire small intestine or even in the local intestinal
submucosal tissue compartment.
It is assumed that the tissue region of each organ can be
modeled as a single well-stirred compartment. This is
clearly an approximation and effects such as diffusion gra-
dients, countercurrent exchange and heterogeneous organ
blood flows [11–13] will produce small deviations from
this assumption. The exchange between the vascular and
tissue compartments results from diffusion of the free sol-
ute between the blood and this well mixed tissue region
during the passage through the capillary (see Appendix,
fig. 7). The rate of this exchange is determined by the cap-
illary permeability-surface area product (PS), which can
be related to the parameter fclear (see Appendix, eq. 3),
which varies from 0 (impermeable) to 1 (flow limited).
For flow limited solutes (e.g. propranolol), the free water
concentration (c) in the vein leaving the tissue is equal to
the free tissue water concentration.
The major limitation of this model is the representation of
the venous and arterial vascular spaces as single compart-
ments. This means that PKQuest cannot provide an accu-
rate picture of the very early time course of drug
Figure 1
Flow diagram used for PBPK model. Each box represents a
well-stirred compartment and each arrow is an input or out-
put to the organ.
Table 1: Organ Weights and Blood Flows for Standard Human 
(70 Kg, 20% Fat)
Organ Weight (Kg) Blood Flow 
(lit/min/Kg)
Artery 1.1 ----
Vein 4.4 ----
Liver 1.8 0.25 (hepatic 
artery)
Portal 1.5 0.75 (portal 
vein)
Kidney 0.31 4.0
muscle 33.0 0.0266
brain 1.4 0.56
heart 0.33 0.8
lung 0.536 14.98
skin 2.6 0.12
fat 14 0.056
"other" 4.12 0.054
"bone" 4.90. 0.0BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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distribution (less than a minute) when a more detailed
model of the vascular compartments is required [14].
Determination of physiological parameters
The most important feature of a PBPK is the accuracy and
validity of the physiological parameters (organ weight,
blood flow, volume of distribution, etc.). The major ad-
vantage of a PBPK over a simpler 2 or 3 compartment
model is that, presumably, it returns a higher resolution
view of the way the body handles the drug. This presump-
tion depends on the assumption that the physiological
parameters in the model are correct. A large amount of ef-
fort has been expended on the choice of these parameters
in PKQuest. Initially, the parameters were chosen using
standard references, such as the "Report on the Task
Group on Reference Man" [15] and "Reference values for
resting blood flow to organs of man" [16] and by copying
values used from previous PBPK models [1,17]. Then the
parameters were adjusted to insure that they were in agree-
ment with such features as total blood volume and cardiac
output [18,19], extracellular space [20] and total body wa-
ter [21,22]. Finally, certain parameters were adjusted to
optimize the fit to the pharmacokinetics of selected sol-
utes. For example, muscle blood flow was adjusted to fit
the D2O kinetics [3], fat blood flow to fit the enflurane ki-
netics [2], and total extracellular space to fit the inulin ki-
netics [4]. All of the human physiological parameters are
listed in the "standardhuman" procedure in the PKQuest
program.
Since muscle represents about 50% of the total water vol-
ume, the muscle blood flow and volume are the two most
important parameters in the PBPK. The value of the mus-
cle blood flow would be expected to have large variations
depending on whether, for example, the subject is lying
on a couch with an IV catheter in his arm or is ambulatory
after an oral drug dose. It is a gross approximation to treat
all the muscles as a single compartment with a single
blood flow and some PBPKs have divided the muscle into
a "working" and "resting" compartment [23]. However,
sub-division of the muscle compartment increases the
complexity of the model beyond what is usually justified
by the available data. For this reason, the muscle blood
flow is the parameter that is most frequently varied for the
different studies described in these papers and will be re-
garded as an adjustable parameter. In PKQuest, when the
blood flow of one organ is changed, all the other organ
flows remain the same, so that the total cardiac output is
also changed. The default value for the muscle blood flow
is at the low end of most estimates (0.0266 liters/Kg), rep-
resenting 14% of the cardiac output. In several of the stud-
ies described in these papers, the muscle blood flow has
been increased by up to a factor of two.
The focus in this series of papers is on human pharmacok-
inetics (using the "standardhuman" parameter set). In ad-
dition, a "standardrat" parameter set is included in the
current version of PKQuest. The physiological parameters
for this rat data set have been chosen and refined using the
same approach that was described here for the human
data set.
Implementation
PKQuest is written using the Maple (version 6, 7 or 8)
computer algebra system  [www.maplesoft.com]. This
means that the user must have Maple installed and run-
ning before PKQuest can be used. This limitation is out-
weighed by the advantage of being able to use all of the
features that are preprogrammed in Maple, such as the nu-
merical solution and graphical options. Maple is available
for most operating systems (PC, Mac, Linux) and PKQuest
should run on any system that has Maple installed.
The derivations and mathematic details of the modeling
program are described in the Appendix. PKQuest is so
large and has so many optional features that not all of
them can be described here. The Appendix focuses on the
features of the program that are new and have not previ-
ously been incorporated into a PBPK model, including the
features 4, 5, 6, 7 and 8 listed below. The description of
many other features is available using the Maple "help"
option that has been programmed into PKQuest. This al-
lows the user to enter the name of a term or parameter that
is used in the program and view a description of the fea-
ture and how it should be used. As a typical example, en-
tering the term fclear in the help option pops up a help
page that begins:
fclear[i] is measure of capillary permeability:
                fclear[i] =first pass clearance of solute =(Cartery -
Cvein)/(Cartery-Ctissue) where C's are free water concentra-
tions.
                It is related to the capillary permeability by: fclear
= 1-exp(-fw [artery]*ps/F) for organ i where p=capillary per-
meability, s= capillary surface area, F = blood flow, and fw [ar-
tery] = fraction of solute that is free (unbound) in arterial
blood.
                NOTE that the effective permeability is the product
of the fraction free in blood (fw [artery]) times the classical per-
meability. For cases where fw [artery] is very small, the solute
can become diffusion limited even for solutes with a large cap-
illary ps.
Flow limited case (Cvein=Ctissue): fclear[i] = 1 (=maximum
allowed value)BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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This is the first third of this help page. It goes on to de-
scribe the different options for entering values of fclear[i]
and for varying and optimizing this parameter. Almost
every parameter in PKQuest has a similar help entry.
PKQuest is a large program, consisting of more than 30
separate Maple procedures and a number of Maple work-
sheets. Once the program has been installed, the user only
needs to deal with two simple procedures, each of which
is contained in one worksheet: The first procedure lists the
values of the model parameters that differ from the de-
fault values for the specific solute that is being investigat-
ed. This procedure is labeled with a name that describes
the compound being investigated. The second procedure
calls the data in the first procedure, runs the program and
determines the type of output that is displayed. In the re-
mainder of this paper, the use of these two procedures will
be illustrated by an investigation of the human pro-
pranolol pharmacokinetics.
Experimental data
Three sets of experimental data were used. The first set was
from the paper of Fagan et. al. [24]. It described measure-
ments of the plasma propranolol concentration from 1
minute to 8 hours after a 0.05 mg/Kg dose infused at a rate
of 1 mg/min in 6 young normal males (weight 60–90 Kg).
The second set was the data of Olanoff et. al. [5] for the si-
multaneous IV infusion of 0.1 mg/Kg (infused at a rate of
1 mg/min) of unlabeled racemic propranolol and oral
dose of 80 mg (consisting of 40 mg of the hexadeuterium-
labeled (+)-propranolol hydrochloride and 40 mg of the
dideuterium-labeled (-) propranolol hydrochloride). The
subjects were 6 healthy males weighing 70 to 100 Kg. The
doses were given either to fasting subjects or immediately
after eating a high protein breakfast. The third set was the
experimental measurements of Takahashi et. al. [25] of
the plasma propranolol concentration after oral adminis-
tration of 60 mg of either conventional or long acting pro-
pranolol (Inderal LA) to 10 healthy subjects (4 females, 6
males, average weight of 59.1 Kg).
The mean plasma concentrations at each time point were
used for the PBPK fitting. The experimental data points
were obtained by using UN-SCAN-IT (Silk Scientific Cor-
poration) to read the data from the published figures.
Results
Summary of features
PKQuest has a number of novel features, many of which
have never before been implemented in a PBPK.
1) There is a large set of default parameters (e.g. organ vol-
umes, blood flows, volume of distribution) that can be
called upon. For example, all the values required for hu-
man studies are setup simply by a call to "standardhu-
man". (The current version also implements a
"standardrat"). The default case assumes that the solute is
lipid soluble, distributes in all the body water, has a very
high capillary permeability (is flow limited) and is not
volatile (no pulmonary exchange). Each of these assump-
tions can be easily modified. For example, if the drug dis-
tributes only in the extracellular space, the user need set
only the parameter "mecf" equal to 1 and PKQuest will
now use the default set of extracellular volumes for each
organ [4]. Or, if the drug is not flow limited but has a sig-
nificant capillary permeability limitation, the user needs
only to input a clearance value for the muscle capillaries
("fclear [muscle]") and all the other organs will have their
permeability set on the basis of their blood flows and ref-
erence permeability surface (PS) product values relative to
muscle [4]. As a another example, if the drug is volatile so
that pulmonary exchange is important, the user need only
input values for the two parameters Kwair (water/air par-
tition coefficient) and Kfwat (fat/water partition) and all
the appropriate parameters necessary for a respiratory
compound are activated [2]. Any or all of the default val-
ues can be easily set to arbitrary, user prescribed, values.
2) The output is routinely displayed in graphical form (in
addition to the standard numerical output). No user input
is required to specify the routine graphical output. All of
the figures shown in this paper are taken directly from the
output of PKQuest without any modifications. Experi-
mental data can be either typed in or read from a tabular
file.
3) A chosen set of parameters can be optimized to give the
best fit to the experimental data. PKQuest uses a rigorous
non-linear global (simulated anealling [26,27]) and local
(Powell, [28]) minimization routines that have a simple
interface. For example, if the user wanted to find the best
set of values for the Vmax and Km for the liver metabo-
lism, and for the muscle blood flow ("F"), it is only neces-
sary to input "adjustn" = 3; and "adjustvar" =
["Vm[liver]","Km[liver]","F[muscle]"]. Any of the param-
eters used in the model can be optimized using this type
of call and there is no limit to the number that can be si-
multaneously optimized (although, in most cases, simul-
taneous optimization of more than 3 parameters is not
recommended, given the limited experimental data).
4) The rate of intestinal absorption (PO, defined as the
rate of uptake by the portal vein) of a drug can be deter-
mined from the experimental venous blood levels after an
oral dose. A new technique is used to invert the model
equations in order to obtain an accurate solution for the
PO absorption. This is a useful new application of PBPK,
providing the user with an accurate time course (and
graphical output) of the oral absorption rate (or, option-
ally, intramuscular, intraperotineal, or skin absorption)BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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for any drug whose PBPK parameters have been previous-
ly determined. This is probably the single most important
original feature in PKQuest, opening up a new approach
to a number of pharmacokinetic problems. An example of
the potential of this tool is illustrated in the application to
propranolol discussed below.
5) The first pass liver metabolism (FPM) and systemic (pe-
ripheral) availability of a PO administered drug is directly
determined and plotted as output. (Systemic availability
is defined as the equivalent IV input that would produce
an identical venous concentration as a function of time as
the PO input). This determination uses a new definition
of FPM that is applicable to the case of non-linear (satura-
ble) liver metabolism. As has been discussed previously
[29], the classical definition of FPM breaks down for the
non-linear case and this is the first rigorous approach to
describing this case. This aspect of PKQuest is presented in
more detail in an accompanying paper that focuses on
ethanol pharmacokinetics [3].
6) Plasma and extracellular protein binding is treated rig-
orously. Since the majority of drugs have some protein
binding, an accurate modeling of this property is essen-
tial. The option of non-linear (saturable) protein binding
is also included. Because this saturation greatly compli-
cates the mathematics of the model, it is rarely included in
PBPKs. PKQuest also allows for a combination of capil-
lary permeability limited exchange and non-linear bind-
ing – the first time this case has been described and
implemented. These features are described in more detail
in an accompanying paper that discusses the application
to antibiotics [4].
7) Although it is well recognized that capillary permeabil-
ity may limit the blood-tissue exchange of a drug, most
PBPK models deal only with the high capillary permeabil-
ity (flow limited) case. PKQuest provides for a rigorous
modeling of capillary permeability limitations. It is
shown in an accompanying paper [4] that solutes that are
normally assumed to be flow limited can have a signifi-
cant capillary permeability limitation if there is a high de-
gree of plasma protein binding.
8) The model of the lung used in PKQuest for the respira-
tory gases allows for the option of ventilation-perfusion
mismatch. The lung can be divided into an arbitrary
number of compartments (determined by the parameter
N1dim) with a log normal distribution of flows and ven-
tilation to each compartment determined by the either the
default or user input values of the log standard deviation
of ventilation (sig_v) and perfusion (sig_f). This feature is
described in more detail in an accompanying paper that
analyses the pharmacokinetics of volatile solutes [2].
9) PKQuest can be used to describe an arbitrary number
of simultaneously interacting solutes. Two types of inter-
action (competitive or non-competitive inhibition) are al-
lowed. Also, the case where some solutes are converted
into other solutes can be modeled, with a separate Vm and
Km for each substrate/product pair.
PKQuest parameters for propranolol intravenous (IV) in-
put
Some of these features will be illustrated by application of
PKQuest to propranolol pharmacokinetics. A baseline set
of physiological PBPK parameters will be determined us-
ing the IV data of Fagen et. al. [24]. This data was chosen
because it represents one of the most complete sets of pro-
pranolol data, with plasma values ranging from 5 minutes
to 8 hours. Shown below is the listing for the procedure
"prop_iv_fagen", which inputs all of the unique parame-
ters that are required. These values have been adjusted to
provide a good fit to the Fagen et. al. data.
prop_iv_fagen:=proc()
defaultpar():
Wtot:=82.0; # Total body weight
standardhuman(Wtot);
Fat:=0.20;# Fat fraction
cunit:="micrograms";
concunit[vein] :=4;# input is plasma venous concen-
tratin
rblpl:=0.85; # blood/plasma concentration ratio
freepl:=0.08;#fraction free in plasma
for i from 2 to N do
ktiss[i]:= 9.67; #tissue/blood partition coefficients
end do;
ktiss[lung]:=29.0; # tissue/blood partition coefficient
for lung
ktiss[lipid]:=2.42;# tissue/blood partition coefficient
for fat
ktiss[muscle]:=3.62;# tissue/blood partition coeffi-
cient for muscle
Tclr[liver]:=52;# metabolic liver clearanceBMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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datafile:="C:/Documents and Settings/DLevitt/My
Documents/mymaple/scandatda/
prop_iv_0_480_new"; pdata:=1;data[1]:=readtab(data-
file);
ninput:=1
finput[1]:=table([organ=vein,type=1,rate=1000,tbeg
=0,tend=4.1,csteady=0,
pad just=0]);#constant infusion of 1000 micro-
grams/min for 4.1 min
end proc;
The first line in the procedure ("defaultpar()") calls an-
other procedure that sets up all the default parameters.
The second line (Wtot) is the total body weight. It is the
only parameter that must be set before the call to "stand-
ardhuman". (The weight is arbitrary for this data because
the dose was scaled for body weight. The value of 82 Kg
was chosen because it is the average value for the Olanoff
et. al. data, see below). The forth line is the fraction of
body weight that is fat. The fifth line ("cunit") sets the
amount unit that is used to micrograms. In PKQuest, the
units of volume, weight and time are always liters, Kg and
minutes. Thus, for this case, the concentration units are
micrograms/liter. The parameter cunit is not needed for
the actual calculations, but is used to label the printed
output data and the axis of the output plot. Line 6 ("con-
cunit") determines the units that are used for the experi-
mental input value. In this case, concunit[vein] = 4
indicates that the experimental input data corresponds to
the venous plasma concentration. Line 7 ("rblpl") is the
blood/plasma concentration ratio. If this is not entered
then a default value will be used. However, in this case the
experimental value is known [7].
The next 7 lines (lines 8–14) are related to the lipid bind-
ing of propranolol. Propranolol blood and tissue binding
has been studied in great detail [7,30–32]. The pro-
pranolol tissue distribution seems to be determined pri-
marily by the phosphatidylserine composition of the
tissue [33]. These studies indicate that the factional bind-
ing is constant, and does not saturate over the pharmaco-
logical concentration range. Since drug binding is such a
ubiquitous property of kinetic studies, PKQuest has incor-
porated a large number of different ways that the data can
be entered. In this case, 2 sets of data are required: freepl,
which is the fraction free in plasma and is set in line 8 to
the experimental value [7] and ktiss[i], the ratio of the
equilibrium tissue/plasma concentration which is set in
lines 9–14. Lines 9–11 set ktiss = 9.67 for all the organs,
and lines 12–14 reset the ktiss for 3 organs that are known
to have distinct binding (lung, muscle and lipid). Tissue
binding studies indicate that propranolol binding in the
lung is about 3 times higher, and muscle is about a third
of that of most tissues. Somewhat surprisingly, pro-
pranolol binding to fat tissue is less than the rest of the
body as indicated by a smaller volume of distribution
(when normalized for body weight) in obese people [34].
Although these values of ktiss[i] are similar to the experi-
mental measurements in the rat [33], they have been
slightly adjusted to improve the fit.
It is well established that the liver is the major site of pro-
pranolol clearance. Line 15 (Tclr [liver]) is the input data
describing the liver metabolism. Although it has been
shown that the liver metabolism is non-linear, saturating
at high blood levels, this non-linearity only becomes sig-
nificant at doses above 200 mg/day [35]. At lower doses,
both the liver metabolism and PO absorption appear to
be linear [36,37]. All the data that will be used here fall in
this linear dose range. In PKQuest, there are 2 options for
entering the metabolism of each organ i. If metabolism is
non-linear, than the 2 parameters Vmax[i] and Km[i] are
required and the rate of metabolism of organ i is described
by Vmax[i]*c[i]/(Km[i] + c[i]) where c[i] is the free con-
centration in the water of organ i. If the metabolism is lin-
ear, than metabolism is described by the parameter Tclr[i]
(rate of metabolism = Tclr[i]*c[i]). Since the propranolol
liver metabolism is linear, it is described by inputting a
value of Tclr [liver] of 52 liters/min. This value was deter-
mined by using the Powel minimization feature in
PKQuest to optimize the fit to the experimental data. Tclr
is the "intrinsic" clearance (liters/min) of the liver, relat-
ing the rate of metabolism to the free water liver concen-
tration. This intrinsic clearance differs significantly from
the actual liver clearance (volume of plasma cleared in
one pass through the liver) because the liver clearance is
partially flow limited and the free water concentration is
lower than the absolute concentration. Although there is
some stereoselectivity in the propranolol metabolism, the
effect is small and was neglected in this analysis [38,39].
Line 16 ("datafile") is the name of the computer tabular
file where the data (time, concentration) is stored. In line
17, "pdata" is the number of input files, and the data is
read into data [i = 1].
The last 2 lines specify the experimental input functions.
The parameter "ninput" is the number of input functions.
In this case there is only one – described by the Maple ta-
ble "finput[1]". The table parameter "organ" is the com-
partment that the input entered – in this case (IV input)
the venous compartment. The parameter "type" specifies
the mathematical form of the input (0 = bolus, 1 = con-
stant infusion, 2 = exponential, 3 = Hill type). In this case
there was a constant infusion at a rate of 1000 micro-BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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grams/min starting at tbeg = 0 and ending at tend = 4.1
minutes. (See below for an example of multiple inputs.)
This completes the description of the data entry for pro-
pranolol. There are really only 2 sets of values that are spe-
cific for propranolol: the lipid binding parameters (freepl
and ktiss[i]) and the liver clearance (Tclr [liver]). All the
rest of the entries (body weight, concentration units, data
file, etc.) are essentially housekeeping. The default param-
eters (set up by the call to "defaultpar") are for the case
that the solute is flow limited and distributes in all the
body water. Since this is the case for propranolol, the pa-
rameters describing the volume of distribution and capil-
lary permeability do not need to be input.
PKQuest output for this set of model parameters
Using this propranolol data, PKQuest is ready to be run. A
listing of the procedure "pkquest" is shown below:
pkquest:= proc()
prop_iv_fagen();
modelplot:=table([n = 1,(ip,1)=vein,mstart=da-
ta[1][1][1],
mend=data[1] [nops(data[1])][1]);
cdata:=vein;
calculate(adjustn,adjustvar,farea,findabs);
end proc;
The first line of the procedure calls the data listed above in
the procedure "prop_iv_fagen". The second line calls for
the standard graphical output. In this case, PKQuest will
output the plot of just the venous concentration (n = 1,
(ip,1)=vein) starting at the time of the first experimental
data point (data[1][1][1]) and ending at the time of the
last data point (data[1] [nops(data[1])][1]). (Up to 6 dif-
ferent organ concentrations can be plotted on the same
graph). The third line ("cdata") specifies that the venous
concentration at the experimental data time points will be
printed in addition to the graphical output. The last line
(calculate) runs the program.
The PKQuest graphical output is shown in fig. 2. (The en-
tire run took less than one second on a 1 Ghz PC). The sol-
id line is the model plasma concentration and the open
squares are the experimental data. The complete layout of
this figure (axes, labels, etc.) is determined without any
user input. Maple has a variety of export options. The fig-
ures shown here have been exported in jpg format.
PKQuest also prints out information pertinent to each
particular case, such as, in this case, the rate of liver metab-
olism, portal and hepatic blood flow, plasma and tissue
binding, etc. PKQuest also routinely outputs the classical
pharmacokinetic values for the experimental data:
Classical Phamacokinetics from Experimental Data (ex-
trapolate to infinity): AUC = 3003.4840 AUMC =
557363.9367 MIT(min) = 2.05 clearance(lit) = 1.3651
Steady State Vol. Dist.(lit) = 252.6390
where the total clearance and steady state volume are de-
termined from the AUC and AUMC (the area under the
curve and its first moment), and MIT (the mean input
time) [40].
Application of PKQuest to simultaneous PO and IV input 
data
Olanoff et al. [5] simultaneously administered unlabeled
propranolol intravenously (IV), and deuterium labeled
propranolol orally (PO) and measured the plasma levels
of the labeled and unlabeled drug. Since the propranolol
pharmacokinetics are linear for this dose, these two inputs
can be treated as completely independent and non-inter-
acting. These experiments will be used to quantitate the
influence of food on propranolol plasma levels.
The approach that will be used is based on finding a set of
PBPK parameters that are consistent with the simultane-
ous PO and IV input data. The model parameters must
meet the following three criteria: 1) Since the measure-
ments are simultaneous, an identical set of parameters
must be used in the modeling of the IV and oral input da-
ta. 2) The PKQuest plasma levels for the IV input must fit
Figure 2
Comparison of PKQuest model prediction and experimental
plasma propranolol concentration data (squares) of fagen et.
al. [24].BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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the observed plasma values. 3) The PKQuest total absorp-
tion for the oral input plasma data must be equal to the
total experimental oral dose of 80 mg. These are quite re-
strictive conditions. This process will be carried out for
both the fasted (fig. 3) and meal case (fig. 4) in order to
determine the effect of the meal on the propranolol phar-
macokinetics.
Figure 3 shows the PKQuest output for the case where the
propranolol was given to fasted subjects simultaneously
by the IV (fig. 3A) and PO (fig. 3B) route. Figure 3A shows
a comparison of the experimental plasma data and model
predictions when the propranolol was given IV (0.1 mg/
Kg). Figure 3B shows the PKQuest calculation of the time
course of the intestinal absorption (open squares) deter-
mined using the experimental plasma values for the oral
propranolol administration. Note that, as required, the
predicted total absorption equals 80 mg, the experimental
oral dose. The same set of parameters is used for both figs.
3A and 3B. All of the parameters are identical to those
used above (fig. 2) for the Fagen et. al. [24] data except
that it was necessary to reduce the portal blood flow by
25% from the default value used in fig. 2 in order to satisfy
the three criteria stated above. This strong dependence on
portal flow arises from the fact that the liver clearance is
limited by liver blood flow for an IV dose, while the first
pass clearance of an oral dose is relatively independent of
liver flow. This relationship can be quantitated and Korn-
hauser et. al. [7] used measurements of the AUC after an
IV and oral dose to estimate the total liver blood flow. In
addition, the muscle blood flow was doubled for the fit in
fig. 3 in order to slightly improve the fit. It is not clear
whether this change in muscle flow has some physiologi-
cal significance or is basically a sort of "fudge factor".
For the output shown in fig. 3B, the parameter "findabs"
was set = 1. This tells PKQuest to use the input blood lev-
els to determine the intestinal absorption rate (see Appen-
dix for details). (Setting findabs = 2 will find the rate of
input into the venous compartment, corresponding to IM,
IP or skin absorption). Figure 3B shows the standard, de-
fault PKQuest output format for this option. The open
squares are the total predicted absorption as a function of
time. The solid line is a 3-parameter approximation to the
actual model total absorption (absorption at time t = A
[tH/(tH +TH)] where A = total absorption, H = Hill expo-
nent, T = half time). In most cases this provides a good ap-
proximation to the PO absorption [3]. However, in this
case the approximation is poor because of the unusual
long initial delay in the propranolol absorption (see be-
low for discussion). The open triangles are the total
amount of systemically (peripherally) available pro-
pranolol, determined by finding the equivalent IV input
that would produce the same plasma levels (see Appen-
dix, section III, for details). The difference between the to-
tal absorption (squares) and peripheral availability
(diamonds) is the first pass liver metabolism. The time de-
pendence of the PO absorption has an initial delay of 30
to 40 minutes, followed by a relatively rapid rate of ab-
sorption that is nearly complete within about 2 hours.
A test of the accuracy of this determination of PO absorp-
tion using plasma concentration data that mimics the ex-
perimental data for propranolol is described in the
Appendix, section VI. For this test case, the total predicted
absorption differs from the actual total PO input by less
than 1%.
The next step is to repeat the above calculations, but this
time using the simultaneous IV and oral data when pro-
pranolol is administered at the same time as a standard
meal (660 calorie high protein breakfast [5]). As before,
since the two sets of data are obtained simultaneously, ex-
actly the same set of physiological parameters must be
Figure 3
Comparison of PKQuest model prediction and experimental data for fasted subjects. Figure 3A shows the predicted venous
plasma concentration for IV propranolol, and fig. 3B shows the predicted time course of absorption (squares) and peripheral
availability (diamonds) for oral propranolol using experimental data of Olanoff et. al [5].BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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used for the IV and oral calculations. Some of these pa-
rameters should differ from those used for the above cal-
culations (fig. 3) because of the changes induced by the
meal. It is well established that portal blood flow is in-
creased during a meal. Direct measurements in humans of
the time course of portal blood flow after a meal show an
increase of between 50 and 100% that peaks 30 to 60
minutes after the meal [8–10]. Olfanoff et. al. [5] found
an average meal induced increase in total liver blood flow
of about 34% using indocyanine green [5]. It has also
been shown that the serum propranolol binding is not af-
fected by meal induced variations in fatty acids [30] so
that the model parameters related to lipid binding (freepl
and ktiss[i]) were not allowed to vary between the fasting
and standard meal experiments.
As described above, meals have a bi-directional effect on
blood levels: decreasing the plasma concentration (and
AUC) when propranolol is given IV, and increasing the
levels (and AUC) when given orally. This bi-directional
meal effect could not be fit just by varying the portal
blood flow. In order to quantitatively fit the meal data, it
was necessary to increase the value used above for the
Olanoff et. al fasting portal blood flow (F [portal]) by
50% and decrease the "intrinsic" liver propranolol clear-
ance (Tclr [liver]) by 20%. The increased portal flow is
consistent with the indocyanine green measurements of
Olanoff et. al. [5]. Figure 4 shows the PKQuest fit to the
meal data using this modified parameter set. As before,
the requirements of a "successful" fit to the simultaneous
data is that the IV input model curve fit the observed plas-
ma concentration (fig. 4A) and the predicted total absorp-
tion for the PO input case (fig. 4B) equal the actual
amount administered (80 mg).
Application of PKQuest to a slow release form of pro-
pranolol
In this section, PKQuest will be applied to the data of
Takahashi et. al [25] in which the oral absorption (in fast-
ing subjects) of a sustained release form of propranolol
(Inderal LA) was compared with the standard form in
same set of subjects. The PBPK parameters used for these
Figure 4
Same as figure 3 for case where propranolol is given either IV or orally at the same time as a standard meal.
Figure 5
Time course of absorption (squares) and peripheral availability (diamonds) for oral (60 mg) standard (fig. 5A) or long acting (fig.
5B) propranolol using experimental data of Takahashi et. al [25].BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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subjects were identical to those determined above for the
IV data of Fagen et. al. [24], except that the value of Tclr
[liver] was adjusted (increased by 50% per Kg body
weight) so that the total absorption for the standard pro-
pranolol equaled the total oral dose (60 mg). Figure 5
shows the predicted time course for the experimental data
for oral administration of the standard form (fig. 5A) and
the long acting form (fig. 5B). It can be seen that the ab-
sorption rate is markedly slowed. There appears to be a
significant absorption rate even for the last data point at
24.5 hours. It can also be seen that only about 50% of the
slow release form is absorbed by 24 hours (30 mg absorp-
tion of the 60 mg dose). It is possible that a higher absorp-
tion faction would have been seen if the plasma
measurements were carried out for longer times. This re-
sult is consistent with the absorption estimate of 60% of
Takahashi et. al [25], based on measurements of the 48
hour urinary excretion of 6 metabolites of propranolol.
Once the PBPK parameters have been determined,
PKQuest can be used to predict the blood levels for an ar-
bitrary set of input functions. For example, using the
above analysis, one can determine the blood levels after
different dosage regimens of the standard and long acting
forms of propranolol. This will be illustrated by a compar-
ison of the blood levels of a daily dose of 120 mg of the
standard form given in 40 mg doses, 3 times a day (at 8
hour intervals) versus 120 mg of the sustained release
form (Inderal LA) given once a day. (According to the
Physicians Desk Reference, these are roughly equivalent
therapeutic doses). The PO absorption rate (Q(t)) is de-
scribed by the 3 parameter Hill equations obtained from
the PKQuest output shown in fig. 5A (standard) and 5B
(long acting) where Q(t) = A [tH/(tH +TH)] and A = total
absorption, H = Hill exponent, T = half time. For the case
of the 3 times per day 40 mg standard dose: A = 40000 µg,
H = 2.67, and T = 122.1 (fig. 5A). For the case of the once
per day 120 mg long acting dose: A = 60000 µg; H = 2.25
and T = 499.2 (fig. 5B). The value of A (total amount ab-
sorbed) for the long acting form was assumed to be 60
mg, 50% of the total 120 mg dose.
PKQuest has a simple interface for entering arbitrary input
doses. The following input is for the case of 4 consecutive
40 mg doses of the standard form at 8 hour intervals:
ninput:=4;
finput[1]:= table([organ=liv-
er,type=3,rate=40000,tbeg=0,tend=122.1,hn=2.67,cstead
y=0,padjust=0]);
finput[2]:= table([organ=liv-
er,type=3,rate=40000,tbeg=480,tend=122.1,hn=2.67,cste
ady=0,padjust=0]);
finput[3]:= table([organ=liv-
er,type=3,rate=40000,tbeg=960,tend=122.1,hn=2.67,cste
ady=0,padjust=0]);
finput[4]:= table([organ=liv-
er,type=3,rate=40000,tbeg=1440,tend=122.1,hn=2.67,cst
eady=0,padjust=0]);
The input is PO absorption directly to the liver (organ=liv-
er), described by the Hill equation (type = 3) with A, H
and T indicated by rate, tend and hn, respectively. The pa-
rameter tbeg indicates the start time in minutes of each in-
put. (The parameters csteady and padjust are not used for
this case). Figure 6 shows the predicted blood levels using
the Takahashi et. al. PBPK parameters for the 3 times per
day standard propranolol (fig. 6A) and the once per day
long acting form (fig. 6B). (This calculation of blood lev-
els for 32 hours required 1.7 seconds on a 1 Mhz compu-
ter). It can be seen that the once per day 120 mg long
acting dose has significantly lower blood levels then the
same daily dosage of the standard form.
Discussion and Conclusions
Overview of novel aspects of PKQuest
PKQuest differs from other PBPKs in that it has been de-
signed to be a complete general-purpose modeling pro-
gram. To this end it includes all the different features that
are required to model the commonly investigated com-
pounds. In this and the accompanying papers [2–4], ex-
amples of the application of PKQuest to the human
kinetics for D2O, inulin, propranolol, ethanol, toluene,
anesthetic gases, ceftriaxone and dicloxacillin (protein
bound antibiotics) are presented. All of these studies use
the same set of basic physiological parameters. (For most
of these compounds, these results represent the first com-
plete human PBPK.) These compounds cover most of the
range of chemical properties that one would expect to en-
counter in a pharmacokinetic study. The pharmacokinet-
ics of different solutes depends on different sets of PBPK
parameters. For example, the time course of the distribu-
tion of D2O [22] has a strong dependence on the cardiac
output, muscle blood flow and total body water, while the
kinetics for inulin [41] have a strong dependence on the
extracellular volume and capillary permeability Knowing
that the same PBPK (using the same set of parameters) is
applicable to a large variety of compounds increases ones
confidence in the validity of the parameters.
The three accompanying papers illustrate other novel fea-
tures of PKQuest: a) quantitation of first pass metabolism
for non-linear liver metabolism [3]; b) measurement of
capillary permeability [4]; c) description of non-linear
plasma and tissue protein binding [4]; d) pharmacokinet-
ics of volatile solutes [2]; and e) importance of perfusion-
ventilation mismatch [2]. Each of these papers providesBMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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significant new information about intensively investigat-
ed solutes.
The most important of the new features is the option that
provides a quantitative measurement (and graphical out-
put) of the time course of the intestinal absorption and
peripheral (or systemic) availability. Calculations of intes-
tinal absorption have been incorporated into earlier PBPK
calculations based on the assumption that intestinal ab-
sorption could be described by either a simple first order
rate process [42–44], or by a pseudo two [45] or N [46]
multi-compartment process. These intestinal compart-
mental parameters were then adjusted to provide the op-
timal fit to the observed blood time course. In contrast, in
PKQuest, the PBPK equations are directly solved for the
intestinal absorption time course without any assump-
tions about the physical or mathematical form of the ab-
sorption process.
If the system is linear, another method of estimating the
intestinal absorption or peripheral availability is by the
application of the deconvolution approach to the blood
levels after an IV and PO input in the same subject [47].
For the peripheral availability, this technique provides a
direct approach with a minimum of model assumptions.
In contrast, the intestinal absorption cannot be directly
determined by the deconvolution approach without some
additional assumptions [47] or by using experimental
Figure 6
Simulated venous plasma concentration for oral administration of standard (fig. 6A) and sustained release (fig. 6B) form of pro-
pranolol: A) Standard form: 40 mg, three times per day; B) Sustained release form: 120 mg, once per day.
Figure 7
Diagram showing the parameters involved in the exchange of solute between the capillary and the extravascular (tissue) space.
The variable C is the total concentration, c is the free water concentration and F is the blood flow. The subscript A indicates
arterial, T tissue and V venous compartments.BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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measurements of the systemic blood levels produced by
portal vein input [48,49]. Thus, the intestinal absorption
feature of PKQuest should provide a useful new applica-
tion even for the linear case.
The use of PKQuest to determine the intestinal absorption
or peripheral availability requires that PBPK parameters
first be determined using the IV input measurements.
However, this does not mean that these measurements
must be made in the same individuals (as is a requirement
for the strict deconvolution approach). For example, in
the above measurement of the rate of intestinal absorp-
tion of the long acting form of propranolol, no IV input
information was available for these subjects. The PBPK
parameters for these subjects were determined by using
the previously determined parameters, inputting the body
weight and fat fraction for these subjects and by using the
assumption that the short acting form was completely ab-
sorbed to determine the value of the intrinsic liver clear-
ance for these subjects.
The term "intestinal absorption" used in PKQuest refers to
the total amount that enters the portal vein. Drug that is
absorbed and then metabolized by the GI tract before en-
tering the portal vein will be treated as if it was never ab-
sorbed. For the special case of a drug that is known to be
completely absorbed (e.g. ethanol), the difference be-
tween the total PKQuest "absorption" and the total PO
dose is a measure of the GI tract drug metabolism.
PKQuest provides the first, rigorous, operational defini-
tion of peripheral availability and first pass metabolism
(FPM) for the non-linear case. As discussed in detail in the
application of PKQuest to ethanol metabolism [3], confu-
sion about the definition of FPM has been the cause of a
controversy regarding the relative importance of gastric
metabolism in the overall ethanol metabolism.
One of the most important applications of animal PBPKs
is to predict the time course of drug levels in different tis-
sues. This feature must be used warily when applied to hu-
mans because the tissue partition coefficients are, in most
cases, not directly measured but are extrapolated from an-
imal measurements. The successful prediction of the ve-
nous plasma concentrations (e.g. figs. 2,3,4) does not
guarantee that the correct tissue partition coefficients have
been used, especially in organs with small volumes (e.g.
brain) that have little influence on the total body disposi-
tion. The output of PKQuest allows the simultaneous dis-
play of the concentrations in up to 6 different organs.
Effect of meals on propranolol pharmacokinetics
The application of PKQuest to the simultaneous measure-
ments of Olanoff et. al. [5] indicates that a meal has two
actions on propranolol metabolism: 1) An increase in
portal blood flow; and 2) A decrease in the intrinsic liver
metabolism of propranolol. This meal induced increase in
portal blood flow is a well documented effect [5,8–10]. In
contrast, the decrease in metabolism has not been previ-
ously quantitated and Olanoff et. al. [5] suggested that the
increase in portal blood flow might be the only change re-
quired to explain the meal effect. The decreased intrinsic
clearance presumably results from some competition in
the liver between the absorbed food products and pro-
pranolol.
There is another rather peculiar effect of meals on pro-
pranolol kinetics that is not usually commented on. A
close look and at the plasma blood level measurements of
Melander et. al. [50] and Walle et. al. [51] reveals that the
peak in the plasma concentration curve for the meal case
occurs at a slightly earlier time than for the fasting case.
This is the opposite of what would be expected because
the meal will significantly delay the rate of gastric empty-
ing which should delay the peak in the plasma concentra-
tion. For example, the peak in the blood ethanol after an
oral dose is delayed by about 20 minutes by a meal be-
cause of the delayed gastric emptying [3,52]. The above
PKQuest analysis provides an explanation for this peculiar
effect. A comparison of figs. 3B and 4B shows that in the
fasting case (fig. 3B) there is a long delay (about 40 min-
utes) before any significant PO absorption occurs. This in-
itial delay is significantly reduced in the meal case (fig.
4B). This 40 minute initial delay suggests that some sort
of change in the state of propranolol (e.g. lipid binding or
micelle formation) is required before it can be absorbed
and that this change is more rapid in the presence of a
meal. Whatever the explanation, this ability to obtain
high resolution information about the time course of PO
drug absorption is a useful feature of PKQuest.
In addition to providing quantitative information about
the rate of PO drug absorption and peripheral availability,
PKQuest also routinely provides a 3 parameter equation
describing the rate of PO absorption that can be used to
predict blood levels for other dosage regimens. This was il-
lustrated above in a comparison of the same total daily
propranolol dose given either 3 times per day using stand-
ard propranolol or once per day as the long acting form.
This same approach can be used to predict blood levels
administered via IM, IP or skin.
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Appendix: Details of PKQuest
I. Given a known input to the animal, solve for the venous, 
arterial and organ concentrations as a function of time
The derivation of the basic set of model equations is de-
scribed here. This derivation takes pains to distinguishBMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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clearly between weights and volumes of organs and flows
and between the total organ concentration and the free
water concentration. In PKQuest, volume, weight and
time are always in units of liters, Kg and minutes. The sol-
ute quantity unit (moles, gms, etc.) is arbitrary and is set
by the user. For illustrative purposes, it has been assumed
below that the unit is moles. The following definitions are
used:
vi = weight (Kg) of organ i
Ci = amount/Kg (mole/Kg) in organ i.
wfracti = fraction of weight of organ i that is water (liters/
Kg)
ci = free concentration in water (moles/liter)
fwi = fraction of the total solute in organ i that is free = ci-
wfracti/Ci
ecfi = fraction of extravascular water that is extracellular
Fi = organ blood flow (liters/min)
PSi = permeability - surface area product for organ i(liters/
min/Kg)
fcleari = fraction solute that equilibrates across capillary in
one pass
Valv = Lung alveolar gas volume per lung weigt (liters/Kg)
alvent = Lung alveolar ventilation rate (liters/min)
ρ B = density of blood (Kg/liter)
k = protein binding constant (moles/liter)-1
Pbi = concentration of protein binding sites in organ i
(moles/liter) Qi = metabolism by organ i (moles/min)
cinputi = external input to organ i (moles/min)
It will be assumed in this section that solute binding is lin-
ear and does not saturate (fwi = constant). The modifica-
tions of the equations required for non-linear binding will
be described in section IV. The solution described in this
section uses the conventional approach that is routinely
used in PBPK models. The only aspect that is novel is the
incorporation of a capillary permeability limitation
through the parameter fcleari.
Figure 7 describes the exchange of solute between the
blood and tissue compartment across the capillary wall. It
is assumed that the tissue consists of N capillaries/Kg, all
with exactly the same geometry, blood flow, permeability,
etc. It will also be assumed that the relation between the
capillary and tissue concentration is in a pseudo steady
state. The steady state differential equation for the concen-
tration in the capillary as a function of position is:
where C and c are the total and free water concentration,
subscript B and T refers to the blood and tissue compart-
ment, P is the capillary permeability, N is the number of
capillaries per Kg tissue, and a is the capillary radius. The
total concentration CB can be related to the free concen-
tration (cB) using the definition of fwb (CB = cBwfractb/
fwb). Integrating eq. 1 over the length of the capillary and
solving for the venous concentration leaving the capillary:
where PS is the permeability-surface area product per tis-
sue weight (liters/min/Kg). Equation 2 can then be related
to capillary clearance term fclear[i] (for organ i) that is
used in PKQuest:
where the dimensionless fclear is equal to the fractional
equilibration that occurs in one pass through the capil-
lary. Note that physical capillary permeability (PS) in eq.
3 is multiplied by fwb, the fraction free in the blood. Thus,
solutes that have a high intrinsic permeability may be-
come permeability limited if a large fraction is bound.
This case is discussed in detail in the application of
PKQuest to protein bound antibiotics [4].
Using eq. 3 to relate the venous concentration (cV) to the
tissue concentration (cT) and the definition of fw to relate
the free to total concentration, the differential equation
for the free tissue concentration in organ i (ci) can be ob-
tained from the mass balance relation for organ i:
where Q is the metabolic utilization and cinput is the in-
put from outside the body. In equation 4, cB is the free
concentration entering the organ. For the lung cB corre-
sponds to the venous concentration and for all other or-
gans cB is the arterial concentration. If the solute can only
distribute in the extracellular space, than the wfracti term
in eq. 4 is replaced by the product ecfi ×  wfracti where ecfi
is the fraction of extravascular water in organ i that is ex-
tracellular.
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The mass balance equation for the lung must be modified
to take account of ventilatory exchange of volatile solutes.
The total concentration of solute in the lung (CL) is the
sum of the solute in the lung tissue compartment plus that
in the alveolar gas space:
(5)   CL = ValvCAlv + CT = ValvCAlv + wfractLcL/fwL
where Valv is the alveolar volume per unit weight (liters/
Kg) and CT is the absolute tissue concentration which can
be related to the free concentration in lung water (cL) via
fwL. It is assumed that the solute in alveolar gas is in equi-
librium with the lung tissue water:
(6)   CAlv = cL/Kwair
where Kwair is the water/air partition coefficient. Thus:
Thus, eq. 4 can also be used for the lung, with fw' substi-
tuted for fw. The cinput term in eq. 4 for the lung can be
written in terms of the alveolar ventilation (alvent, liters/
minute):
(8)   cinputL = alvent(Cinhale - cL/Kwair)
where Cinhale is the inhaled gas concentration (moles/lit-
er). The above equations are for the case where there is
one lung compartment. The modifications for the case of
perfusion-ventilation mismatch is described in section V.
Equation 4 is the mass balance for each organ compart-
ment. We still need to define the mass balance for the ar-
terial and venous compartments. For the artery, the mass
balance is described by:
where the subscript A indicates artery, FCO is the cardiac
output and cL
v is the concentration in the venous blood
leaving the lung. The concentration cL
v can be related to
the venous concentration entering the lung (cV) by the use
of eq.3:
Finally, substituting eq. 10 into eq. 9:
An equation similar to eq. 9 is obtained for the venous
compartment, except that it is necessary to sum over the
venous concentrations leaving each organ, multiplied by
the organ blood flow:
where ci
V is the concentration in the vein leaving organ i.
The sum is over all the organs that empty in to the vein (i
= 0 and 1 correspond to the venous and arterial compart-
ments). The concentration ci
V can be related to the arterial
concentration entering organ i by the use of eq.3:
Finally, substituting eq. 13 into eq. 12:
The set of differential equations for dci/dt, i = 0..11 for
each of the organs (i = 2..11) and the venous (i = 0) and
arterial (i = 1) compartments is then solved by a Runge-
Kutta numerical procedure for the values of ci as a func-
tion of time. The free water concentration ci is then con-
verted to the experimental concentration units and
plotted along with the experimental data. This conversion
depends on exactly what is measured experimentally. In
PKQuest the user inputs the parameter concunit[i] which
characterizes what experimental unit is used. For example,
concunit = 1 indicates total concentration in units of
amount/Kg wet weight; concunit = 2 corresponds to
amount/liter tissue; concunit = 4 corresponds to plasma
concentration, etc.
II. Given the experimental venous concentration as a func-
tion of time, solve for rate of oral (PO) or intramuscular 
(IM) absorption as a function of time
The solution described above in I corresponds to the case
where the input to one or more of the compartments is
given (cinput[i]) and the concentration of the different
compartments as a function of time is solved for. This sec-
tion describes the new procedure that was developed to
invert this solution, and find the value of cinput[i] as a
function of time that would produce the experimental ve-
nous concentration. Although the approach described be-
low can be used for input into any compartment, the
current version of PKQuest implements only two different
inputs: 1) PO input in which the solute is absorbed from
the GI tract and goes directly into the portal vein, where it
distributes in and is metabolized by the liver before enter-
ing the systemic vein; and 2) IV input in which the solute
directly enters the systemic vein. The IV input case is ap-
plicable to any input where there is time dependent input
directly to the venous blood without significant distribu-
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tion in another organ – e.g. intramuscular (IM), intraperi-
toneal (IP) or skin absorption.
Since the venous concentration is known experimentally
at a set of time points, this concentration can be used as
input to the set of equations described in section I (omit-
ting the venous differential equation, since its concentra-
tion is known). The solution to this set of equations then
yields the corresponding arterial and organ concentra-
tions as a function of time. In the implementation in
PKQuest, a cubic spline interpolation is applied to the ex-
perimental data points to obtain a continuous function
cv(t) that is used as input to the set of equations. For the
case of IV input these organ concentrations (as a function
of time) should be equal to the actual organ concentra-
tions in the experimental case, since both cases have the
same venous concentration.
For the PO input case, all the organs will have the correct
concentration except for the liver which receives input
from the GI tract in addition to the venous input. Another
step is required to determine the liver concentration for
this case. The differential equation for the venous com-
partment (eq. 14) can be solved for the liver concentra-
tion (cLiver(t)) since the concentrations in all the other
organs and in the vein are known. (In eq. 14, the cinputv
term is 0 since there is no venous input, and QV is zero be-
cause it is assumed for this case that there is no metabo-
lism in the venous compartment). The only factor in eq.
14 that is not directly available is the time derivative of the
venous concentration (dcv/dt). However, this can be esti-
mated by taking the derivative of the cubic spline interpo-
lation to the experimental venous data. This solution for
the liver concentration is then combined with the previ-
ous solutions to obtain the concentrations of all the body
organs as a function of time for the PO input case.
Knowledge of the concentrations as a function of time of
all the body compartments is all that is needed to deter-
mine the rate of input to the body. The total body input at
time t is equal to the total amount in the body at time t
(obtained by summing over all the body compartments)
plus the total amount that has been metabolized or excret-
ed up to that time – which is obtained by integrating over
the rates of metabolism (Qi) in the different organs, plus
the rate of renal clearance, etc. In the implementation of
PKQuest, this calculated total amount input is plotted as
a function of time. A test of this approach is described be-
low (VI) using data that is representative of what is ob-
served experimentally for propranolol. It is shown that the
total predicted absorption differs from the actual total PO
input by only about 0.5%.
III. Direct calculation of the first pass metabolism or pe-
ripheral availability for the case of PO input
The procedure described above in section II for determin-
ing the rate of PO absorption can be directly used to deter-
mine the first pass metabolism. In the calculation in
section II, two different sets of liver concentrations were
obtained: Case 1) Using just the experimental venous con-
centration as input. Case 2) Using the direct calculation of
the liver concentration via the solution of eq. 14. Case 1
corresponds to the liver (and other organ) concentrations
that would be obtained if the input were intravenous (IV)
and Case 2 is for a PO input. Both cases have exactly the
same venous concentration. This means that both cases
have the same "peripheral availability". Thus, the periph-
eral availability for the PO input case can be obtained by
solving for the IV input as a function of time (by summing
over the amounts in each organ plus the amount of me-
tabolism) using the organ concentrations for Case 1. This
is a direct measure of what the time course of the IV input
would have to be to give exactly the same venous concen-
trations as occurred for the PO input. The first pass metab-
olism (FPM) is directly related to the peripheral
availability by the following relation:
First Pass Metabolism = Total Absorption - Peripheral
Availability
In the implementation of PKQuest for the PO absorption
case, both the total amount of PO absorption and the pe-
ripheral availability are routine plotted as a function of
time.
This is a new definition of first pass metabolism. It pro-
vides the first rigorous, operational definition of FPM that
is applicable to the non-linear liver metabolism case. This
case is discussed in more detail in the paper describing the
application of PKQuest to ethanol pharmacokinetics [3].
IV. Modifications of above equations for the case where 
there is non-linear (saturable) protein binding
Allowing for non-linear protein binding seriously compli-
cates the model. It corresponds to the case where the fwi
in the above equations becomes a function of ci(t) and it
requires major modifications of all of the equations. The
modifications described below are similar to those used
previously by Tsuji, et. al. [53], but with the new feature of
including the capillary permeability. This is the first de-
scription of a PBPK model that allows for both non-linear
binding and capillary permeability.
The modifications of the left and right hand sides of eq. 4
will be described separately. The left hand side described
the change in the total (bound + free) concentration in or-
gan i:BMC Clinical Pharmacology 2002, 2 http://www.biomedcentral.com/1472-6904/2/5
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where, as previously defined, ci is the free water concentra-
tion, and cb
i is the concentration of the bound solute in
the organ water. It will be assumed that there is only one
homogeneous binding site with the classical Scatchard
type binding described by:
where k is the binding constant for the protein and Pbi is
the concentration of protein binding sites in compart-
ment i. Pb must have the came units as c (e.g. moles/liters)
and k has the inverse units (e.g. 1/(moles/liters)). It is as-
sumed that there is only one type of binding protein (with
a unique k) that is distributed with different concentra-
tions (Pbi) in the different compartments. Taking the de-
rivative of cb
i (eq. 16) and substituting it in eq. 15:
For the limiting case where binding does not saturate (kci
<< 1), γ i in eq. 17 becomes equal to 1/fwi and eq. 17 be-
comes equal to the left hand side of eq. 4.
The right hand side of eq. 4 has a term that describes the
balance between the inflow and outflow of blood from or-
gan i:
where cB and ci
v are the free concentration in the blood
water entering and leaving organ i, and cb
B and cb
v are the
bound concentrations entering and leaving the organ. As
before, ci
v can be related to cB and the tissue concentration
ci using fcleari:
Finally, substituting eq. 19 into eq. 18, and equating the
right (eq. 17) and left hand sides (eq. 18), the generaliza-
tion of eq. 4 to include non-linear binding is obtained:
where the new parameters κ B, κ V and γ  are defined as fol-
lows: For the case where the binding is linear:
For the case of non-linear binding (saturation)
There is one other complication introduced by the non-
linear binding. As shown in eq. 3, the fcleari that enters
eqs. 20–22 depends on fwB which, for the non-linear case,
is a function of cB (eq. 16). To take this into account, eq.
3 is solved for the value of fcleari(cB):
where fcleari is the clearance in the limit of 0 concentra-
tion and is the value the user inputs to PKQuest. This last
expression for fcleari(cB) is substituted for fcleari in eqs.
20–22.
V. Modification of lung model to include ventilation-per-
fusion mismatch
The equation in section I for the lung assumed that there
was one lung compartment, perfused by FCO (cardiac out-
put) with an alveolar volume valv that was ventilated at a
rate alvent. This is an idealized case and it is known that
even in normal humans the lung is heterogeneous, with
different regions receiving different fractions of the cardi-
ac output and the alveolar ventilation. In order to investi-
gate the significance of the ventilation-perfusion
mismatch, this feature was incorporated as in option in
PKQuest. This is the first time this feature has been used
in a PBPK.
As was discussed in detail by Wilson and Beck [54] the
standard measurement of the   distribution does
not uniquely characterize the actual ventilation and per-
fusion heterogeneities to the different regions of the lung
and some additional assumptions must be made. The fol-
lowing derivation closely follows the arguments of Wilson
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and Beck [54]. It is assumed that the probability distribu-
tion of ventilation and perfusion can be described as a bi-
variate, uncorrelated, log-normal function:
where µv and µQ are the means and σ v and σ Q are the
standard deviations of the log normal distribution. The
function F returns the fraction of the lung that has venti-
lation   and blood flow   in the interval d ln   and d ln
 centered about ln   and ln  . The function can be
normalized by the use of the normalized variables v and
q:
In the implementation in PKQuest, the lung is divided
into (2N)2 equal volume regions by finding the sequence
of vi and qi (i = 0..N..2N) centered about 0 such that all
integrals of f(v)dv from vi to vi+1 have the same value.
Then each of the regions rij (vi..vi+1, qj..qj+1) has equal ar-
ea. Each lung region rij is assigned a fraction of the total
blood flow ( ij) defined by:
From the definition of q (eq. 25):
where, in the second equality in eq. 27, the relation A21
of Beck and Wilson [54] has been substituted for exp(µq).
Substituting eq. 27 into eq. 26 and integrating, yields the
blood flow to the ij region. A similar approach is used to
find the ventilation to the ij region.
The overall result of this rather messy procedure can be
summarized as follows: The lung is divided into (2N)2
equal volume regions, each region having a ventilation
and blood flow based on the observed log normal distri-
butions. Each region is defined to have the same tissue
and alveolar volume. An important assumption that has
been used here is that the ventilation and perfusion to
each region is uncorrelated. This assumption is consistent
with recent direct measurements of regional perfusion
and ventilation [55,56].
In the implementation in PKQuest, the number of lung
compartments (Nlung) is determined by the parameter
N1dim (Nlung = (2 N1dim)2). The default is Nlung = 1
(indicated by N1dim = -1). Choosing N1dim = 2, means
that the perfusion and ventilation is distributed over 16
lung compartments which should be enough to provide a
good test of the importance of perfusion-ventilation mis-
match. If Nlung>1 then values are required for σ v (sig_v in
PKQuest) and σ q (sig_f). Default values of sig_v and sig_f
are included in standardhuman. These default values were
obtained using the relation of Wilson and Beck [54] that
relates the standard deviation of the   distribution
that is routinely measured (σ v/q) to the values of σ v and
σ q that are required in eqs. 23–26:
where ρ  is the correlation between perfusion and ventila-
tion. The default values in PKQuest are for the case of ρ  =
0, and σ v= σ q and σ v/q = 0.4, the normal value for young
adult men [57]. The user can input arbitrary values by in-
putting sig_v and sig_f. This perfusion-ventilation mis-
match feature is discussed and tested in the paper
describing the application of PKQuest to volatile solutes
[2].
V. Tests of the accuracy of the "find absorption" option of 
PKQuest
The "find absorption" option (see II above for details)
predicts the PO absorption as a function of time based on
the observation of plasma concentration at a set of time
points. The following test of this calculation was carried
out. It is assumed that the PO input is known and can be
described by the following 3-parameter Hill type equation
similar to what was found experimentally for propranolol
in fig:
(29)   Absorption at time t = A [tH/(tH + TH)] where
A = 80000 micrograms, H = 2, T = 90
Figure 8 shows the plasma concentration curve generated
by PKQuest for this known input. The solid line is the
model plasma concentration, and the squares are the val-
ues of the plasma concentration, sampled at the same
time points as the experimental plasma concentration in
the measurements of Olanoff et. al. [5] described in the
text. The test of the "find absorption" feature is to see if
PKQuest can reproduce the time dependent absorption
that was used to generate these points (eq, 29), just using
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these experimental points as inputs. Figure 9 shows the
output of PKQuest using the "find absorption" option us-
ing the data points (squares) from fig. 8 as input. The val-
ue of the total predicted absorption differs from the actual
total input by only 0.5% (80505 versus actual 80000).
The time dependence of the absorption is also quite close
to the actual input function (eq. 29), with the Hill expo-
nent (H) differing by 2% (2.04 versus input 2.0) and the
half time (T) differing by 4% (94.63 versus input 90.0).
This agreement is remarkable, considering the coarse dis-
crete samples of the venous concentration that were used
as input to PKQuest.
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